| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| QSAM Biosciences, Inc. | Director | COMMON STOCK | 400,000 | $1,200,000 | $3.00 | 15 Dec 2021 | Direct |
| CITIUS ONCOLOGY, INC. | Director | Stock Option (Right to Buy) | 250,000 | $522,500 | $2.09 | 19 Sep 2025 | Direct |
| CITIUS ONCOLOGY, INC. | Director | Common Stock | 321,228 | $388,685 | $1.21 | 19 Sep 2025 | Direct |
| QSAM Biosciences, Inc. | Director | Options to buy common stock | 54,000 | 24 Aug 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CTOR | CITIUS ONCOLOGY, INC. | 19 Sep 2025 | 1 | $0 | 4/A | Director | 22 Dec 2025, 16:10 |
| CTOR | CITIUS ONCOLOGY, INC. | 19 Sep 2025 | 1 | $0 | 4/A | Director | 01 Dec 2025, 16:10 |
| CTOR | CITIUS ONCOLOGY, INC. | 28 Jul 2025 | 1 | $0 | 4 | Director | 07 Aug 2025, 17:02 |
| CTOR | CITIUS ONCOLOGY, INC. | 12 Dec 2024 | 1 | $0 | 4 | Director | 16 Dec 2024, 17:05 |
| CTOR | TenX Keane Acquisition | 13 Oct 2022 | 0 | $0 | 3 | Director | 13 Oct 2022, 17:23 |
| /report/000149315222004618-mayersohn-joel-david-2021-12-31 | QSAM Biosciences, Inc. | 31 Dec 2021 | 2 | $0 | 5 | Director | 14 Feb 2022, 20:57 |